A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...
The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...
Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.
A comprehensive single-cell atlas of AML uncovers regulatory networks and age-dependent molecular differences to advance the understanding of disease mechanisms and enable subtype-specific therapeutic ...
Vetnique Labs ("Vetnique"), a leading vet-recommended pet health and wellness company, today announced that consumer industry leader Noel Geoffroy has been named Global CEO, responsible for leading ...
We may earn commission from links on this page, but we only recommend products we back.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results